Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer - A phase II study

BMC Cancer

Volumn 2, Issue , 2002, Pages

  Tomlinson, Shannon K ^a   Melin, Susan A ^a   Higgs, Vetta ^a   White, Douglas R ^a   Savage, Paul ^a   Case, Douglas ^a   Blackstock, A William ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PHOSPHORIBOSYL PYROPHOSPHATE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA SYNTHESIS INHIBITION; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MODULATION; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SCORING SYSTEM; THROMBOCYTOPENIA; ABDOMINAL TUMOR; COLORECTAL TUMOR; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; LIVER TUMOR; LUNG TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION ROUTES; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; METHOTREXATE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 19044368632     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-2-9     Document Type: Article

References (48)

1. Andre T, Bensmaine MA, Louvet C, et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999, 17:3560-8
2. Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998, 16:2739-44
3. Becouarn Y, Rougier P: Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 1998, 25:23-31
4. Diaz-Rubio E, Sastre J, Zaniboni A, et al: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998, 9:105-8
5. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7:95-8
6. Rothenberg ML, Cox JV, DeVore RF, et al: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999, 85:786-95
7. Cunningham D, Glimelius B: A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999, 26:6-12
8. Saltz LB: Irinotecan in the first-line treatment of colorectal cancer. Oncology (Huntingt) 1998, 12:54-8
9. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:709-15
10. Moertel CG: Chemotherapy for colorectal cancer [see comments]. N Engl J Med 1994, 330:1136-42
11. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989, 7:1427-36
12. Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group [published erratum appears in J Clin Oncol 1990 Jan; 8(1):185]. J Clin Oncol 1989, 7:1419-26
13. Jager E, Heike M, Bernhard H, et al: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996, 14:2274-9
14. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994, 12:960-9
15. Erlichman C: 5-Fluorouracil (FUra) and folinic acid (FA) therapy in patients with colorectal cancer. Adv Exp Med Biol 1988, 244:185-92
16. Erlichman C, Fine S, Wong A, Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988, 6:469-75
17. O'Dwyer PJ: Biochemical modulation of 5-fluorouracil by PALA. Cancer Invest 1990, 8:261-2
18. Martin DS: Biochemical modulation of 5-fluorouracil by PALA: mechanism of action. Adv Exp Med Biol 1993, 339:153-63
19. Kemeny N, Conti JA, Seiter K, et al: Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. J Clin Oncol 1992, 10:747-52
20. Rosvold E, Schilder R, Walczak J, et al: Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol 1992, 29:305-8
21. O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL: Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 1990, 8:1497-503
22. Kemeny NE, Schneider A, Martin DS: Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity. Cancer Invest 1990, 8:263-4
23. Pazdur R, Ajani JA, Patt YZ, et al: Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990, 8:2027-31
24. Kim J, Zhi J, Satoh H, et al: Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. Anticancer Drugs 1998, 9:689-96
25. Hansen RM, Ryan L, Anderson T, et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996, 88:668-74
26. Aranda E, Diaz-Rubio E, Cervantes A, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998, 9:727-31
27. Pazdur R: Phase II study of UFT plus leucovorin in colorectal cancer. Oncology 1997, 54:19-23
28. Romanini A, Li WW, Colofiore JR, Bertino JR: Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. J Natl Cancer Inst 1992, 84:1033-8
29. Kamm VJ, Rietjens IM, Vervoort J, et al: Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy. Cancer Res 1994, 54:4321-6
30. Van der Wilt CL, Braakhuis BJ, Pinedo HM, De Jong M, Smid K, Peters GJ: Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? Int J Cancer 1995, 61:672-8
31. Ardalan B, Luis R, Jaime M, Franceschi D: Biomodulation of Fluorouracil in colorectal cancer [see comments]. Cancer Invest 1998, 16:237-51
32. McSheehy PM, Prior MJ, Griffiths JR: Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo. Br J Cancer 1992, 65:369-75
33. Chabner BA: Pyrimidine antagonists. In: Pharmacologic Principles of Cancer Treatment: W.B. Saunders, (Edited by: Chabner BA)1982
34. Santi DV, McHenry CS, Sommer H: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974, 13:471-81
35. Mini E, Moroson BA, Bertino JR: Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. Cancer Treat Rep 1987, 71:381-9
36. Yin MB, Zakrzewski SF, Hakala MT: Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 1983, 23:190-7
37. Cadman E, Heimer R, Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 1979, 205:1135-7
38. Benz C, Schoenberg M, Choti M, Cadman E: Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. J Clin Invest 1980, 66:1162-5
39. Fernandes DJ, Bertino JR: 5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Natl Acad Sci U S A 1980, 77:5663-7
40. Mullany S, Svingen PA, Kaufmann SH, Erlichman C: Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998, 42:391-9
41. Guichard S, Hennebelle I, Bugat R, Canal P: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998, 55:667-76
42. Rostagno P, Formento P, Ciccolini J, et al: Mechanisms of the synergy between oxaliplatin (LOHP) and 5 fluorouracil (FU)-folinic acid (FA). Proc. Amer. Assoc. Can. Res. 2000
43. Hsu C, Yeh KH, Yeh PY, Chen ML, Lin ZR, Cheng AL: Cytotoxicity of oxaliplatin in gastric cancer cells - Studies on single-agent activity and combination effect with 5-fluorouracil. Proc. Amer. Assoc. Can. Res. 2000
44. Stabuc B, Markovic A, Plesnicar A, Cizej TE: Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer [In Process Citation]. Neoplasma 2000, 47:248-52
45. Comella P, Lorusso V, Casaretti R, et al: Concurrent modulation of 5-fluorouracil with methotrexate and L-leucovorin: an effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma. A multicenter phase II study of the Southern Italy Cooperative Oncology Group. Tumori 1999, 85:465-72
46. Polyzos A, Tsavaris N, Giannopoulos A, et al: Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. Cancer Chemother Pharmacol 1996, 38:292-7
47. Romero AO, Perez JE, Cuevas MA, et al: Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer. Am J Clin Oncol 1998, 21:94-8
48. Marsh JC, Bertino JR, Katz KH, et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer [see comments]. J Clin Oncol 1991, 9:371-80